Are macrophages the bad guys in Hodgkin lymphoma?
- 1 June 2010
- journal article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 7 (6), 301-302
- https://doi.org/10.1038/nrclinonc.2010.71
Abstract
Prognostic models for patients with Hodgkin lymphoma are imperfect and do not allow a precise individualized therapy. A recent gene-expression profiling study, translated into a routine immunohistological test, identified genes of tumor-associated macrophages as being responsible for treatment outcome in patients with Hodgkin lymphoma. If this finding is confirmed by other investigators, it could be a major step towards personalized therapy for patients with Hodgkin lymphoma.Keywords
This publication has 10 references indexed in Scilit:
- Toward a Personalized Treatment of Hodgkin's DiseaseNew England Journal of Medicine, 2010
- Tumor-Associated Macrophages and Survival in Classic Hodgkin's LymphomaNew England Journal of Medicine, 2010
- The microenvironment in mature B-cell malignancies: a target for new treatment strategiesBlood, 2009
- The biology of Hodgkin's lymphomaNature Reviews Cancer, 2008
- Current Strategies and New Approaches in the Treatment of Hodgkin’s LymphomaPathobiology, 2006
- Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphomaBlood, 2006
- FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphomaBlood, 2006
- Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune CellsNew England Journal of Medicine, 2004
- Gene expression profiling defines molecular subtypes of classical Hodgkin's diseaseOncogene, 2002
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998